The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.
作者信息
Eng Pei Chia, Distaso Walter, Durreshahwar Hashmi, Shaikhali Yusuf, Narendranathan Divani, Cassin-Scott Rebecca, Misra Shivani, Hill Neil E, Tharakan George, Oliver Nick S, Tan Tricia M, Izzi-Engbeaya Chioma, Salem Victoria
机构信息
Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Division of Medicine and Integrated Care, Imperial College Healthcare NHS Trust, London, UK.
出版信息
Diabetes Obes Metab. 2022 Jul;24(7):1385-1389. doi: 10.1111/dom.14692. Epub 2022 Apr 3.
Abstract
摘要
相似文献
1
The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.地塞米松对2019冠状病毒病感染患者的益处，在糖尿病患者中依然存在。
Diabetes Obes Metab. 2022 Jul;24(7):1385-1389. doi: 10.1111/dom.14692. Epub 2022 Apr 3.
2
Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.COVID-19患者的地塞米松治疗：对糖尿病患者和非糖尿病患者血糖管理的影响及指导
Diabet Med. 2021 Jan;38(1):e14378. doi: 10.1111/dme.14378. Epub 2020 Sep 21.
3
COVID-19 and dexamethasone-induced hyperglycaemia: Workload implications for diabetes inpatient teams.新型冠状病毒肺炎与地塞米松诱发的高血糖症：对糖尿病住院团队工作量的影响
Diabet Med. 2022 Feb;39(2):e14716. doi: 10.1111/dme.14716. Epub 2021 Oct 22.
4
Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.地塞米松对重症 COVID-19 患者是否为有效治疗方法：期刊俱乐部综述。
CJEM. 2021 Mar;23(2):159-161. doi: 10.1007/s43678-020-00033-3. Epub 2021 Jan 4.
5
Dexamethasone and oxygen therapy in care home residents with diabetes: a management guide and algorithm for treatment: a rapid response action statement from the European Diabetes Working Party for Older People (EDWPOP) and European Geriatric Medicine Society (EuGMS).地塞米松和吸氧治疗在有糖尿病的养老院居民中的应用：管理指南和治疗算法：欧洲老年糖尿病工作组（EDWPOP）和欧洲老年医学学会（EuGMS）的快速反应行动声明。
Aging Clin Exp Res. 2021 Apr;33(4):895-900. doi: 10.1007/s40520-021-01822-1. Epub 2021 Apr 15.
6
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.地塞米松对住院 COVID-19 患者 SARS-CoV-2 浓度动力学和抗体反应的影响：一项前瞻性观察研究的结果。
Clin Microbiol Infect. 2021 Oct;27(10):1520.e7-1520.e10. doi: 10.1016/j.cmi.2021.06.008. Epub 2021 Jun 15.
7
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis.地塞米松治疗 SARS-CoV-2 感染：系统评价和荟萃分析。
Sao Paulo Med J. 2021 Oct 11;139(6):657-661. doi: 10.1590/1516-3180.2021.0120.R1.30062021. eCollection 2021.
8
Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19.地塞米松、促消退脂质介质与新冠病毒感染炎症的消退
Allergy. 2021 Mar;76(3):626-628. doi: 10.1111/all.14595.
9
Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality.COVID-19 感染患者出院后接受地塞米松治疗与再入院和死亡率的关系。
JAMA Netw Open. 2022 Mar 1;5(3):e221455. doi: 10.1001/jamanetworkopen.2022.1455.
10
Differential effects of age, sex and dexamethasone therapy on ACE2/TMPRSS2 expression and susceptibility to SARS-CoV-2 infection.年龄、性别和地塞米松治疗对 ACE2/TMPRSS2 表达和对 SARS-CoV-2 感染易感性的差异影响。
Front Immunol. 2022 Nov 3;13:1021928. doi: 10.3389/fimmu.2022.1021928. eCollection 2022.
引用本文的文献
1
Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study.地塞米松对住院糖尿病患者新型冠状病毒肺炎的疗效：一项回顾性队列研究。
J Clin Endocrinol Metab. 2025 Jun 17;110(7):1846-1853. doi: 10.1210/clinem/dgae734.
2
Diabetes Mellitus, Energy Metabolism, and COVID-19.糖尿病、能量代谢与 COVID-19
Endocr Rev. 2024 Mar 4;45(2):281-308. doi: 10.1210/endrev/bnad032.
3
Dexamethasone in patients with diabetes mellitus.糖尿病患者使用地塞米松。
Nat Rev Endocrinol. 2022 Jun;18(6):333. doi: 10.1038/s41574-022-00676-5.
本文引用的文献
1
COVID-19 and dexamethasone-induced hyperglycaemia: Workload implications for diabetes inpatient teams.新型冠状病毒肺炎与地塞米松诱发的高血糖症：对糖尿病住院团队工作量的影响
Diabet Med. 2022 Feb;39(2):e14716. doi: 10.1111/dme.14716. Epub 2021 Oct 22.
2
Modelling hospital outcome: problems with endogeneity.建模医院结果：内生性问题。
BMC Med Res Methodol. 2021 Jun 21;21(1):124. doi: 10.1186/s12874-021-01251-8.
3
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis.糖尿病的风险表型与 COVID-19 严重程度和死亡的关系：一项实时系统评价和荟萃分析。
Diabetologia. 2021 Jul;64(7):1480-1491. doi: 10.1007/s00125-021-05458-8. Epub 2021 Apr 28.
4
Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals.COVID-19 与糖尿病的不良结局：来自伦敦三家教学医院的回顾性队列研究。
BMJ Open Diabetes Res Care. 2021 Jan;9(1). doi: 10.1136/bmjdrc-2020-001858.
5
Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.COVID-19患者的地塞米松治疗：对糖尿病患者和非糖尿病患者血糖管理的影响及指导
Diabet Med. 2021 Jan;38(1):e14378. doi: 10.1111/dme.14378. Epub 2020 Sep 21.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.2020 年，由于潜在健康状况，全球、区域和国家估计有多少人面临 COVID-19 重症风险增加：一项建模研究。
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017. doi: 10.1016/S2214-109X(20)30264-3. Epub 2020 Jun 15.
8
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.COVID-19 合并 2 型糖尿病患者的血糖控制与结局的相关性。
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021. Epub 2020 May 1.
Zotero 插件